Langston JW, Ballard P, Tetrud JW, Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–80PubMedCrossRef

Petzinger GM, Jakowec MW. (2004) The MPTP-lesioned model of Parkinson’s disease with emphasis on mice and nonhuman primates. Comp.Med 54:497–513PubMed

Dauer W, Przedborski S. (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909PubMedCrossRef

Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, et al. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. Journal of Neurochemistry 76:1265–74PubMedCrossRef

Irwin I, Ricaurte GA, DeLanney LE, Langston JW. (1988) The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age. Neurosci Lett 87:51–6PubMedCrossRef

Lau YS, Novikova L, Roels C. (2005) MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neurosci Res 52:371–8PubMedCrossRef

Davey GP, Tipton KF, Murphy MP. (1992) Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode. Biochem J 288:439–43PubMed

Fuller R, Hemrick-Luecke S. (1987) Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Res Commun Chem Pathol Pharmacol 56:147–56PubMed

Fuller RW, Hemrick-Luecke SK. (1986) Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mimicked by 1-methyl-4-phenylpyridinium (MPP+) and not blocked by deprenyl. Life Sci 39:1645–50PubMedCrossRef

Heikkila RE. (1985) Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur. J. Pharmacol. 117:131–3PubMedCrossRef

Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, et al. (1994) Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinium in in C57/bl and CD-1 mice. Experimental Neurology 126:195–204PubMedCrossRef

Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK. (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171–82PubMedCrossRef

Irwin I, Finnegan KT, DeLanney LE, Di Monte D, Langston JW. (1992) The relationship between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Research 572:224–31PubMedCrossRef

Ricaurte GA, DeLanney LE, Irwin I, Langston JW. (1987) Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26:97–9PubMedCrossRef